Literature DB >> 16698091

Altered maturation of circulating dendritic cells in primary progressive MS patients.

Cristina López1, Manuel Comabella, Hammad Al-zayat, Mar Tintoré, Xavier Montalban.   

Abstract

We investigated the phenotype and frequency of circulating myeloid dendritic cells (MDC) and plasmacytoid DC (PDC) in 86 multiple sclerosis (MS) patients and 33 healthy controls (HC). The MS group comprised 20 patients with primary progressive MS (PPMS), 20 patients with secondary progressive MS (SPMS), and 46 patients with relapsing-remitting MS (RRMS) [23 treated with interferon-beta (IFN-beta)]. The frequency of circulating MDC and PDC, and the expression of CD83, CD123, CD80, CD86, and CD40 were analyzed by flow cytometry. The percentage of circulating MDC was decreased in patients with SPMS and PPMS. The expression of CD83, CD80, and CD86 was lower in PPMS patients. Treatment with IFN-beta induced the expression of CD123 in PDC and decreased the number of circulating MDC. These results suggest an impaired maturation state of DC in PPMS patients, and a beneficial effect of IFN-beta favouring the survival of PDC and promoting a Th2 environment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16698091     DOI: 10.1016/j.jneuroim.2006.03.010

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  15 in total

Review 1.  Innate-adaptive crosstalk: how dendritic cells shape immune responses in the CNS.

Authors:  Benjamin D Clarkson; Erika Héninger; Melissa G Harris; JangEun Lee; Matyas Sandor; Zsuzsanna Fabry
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

2.  Plasmacytoid dendritic cells in multiple sclerosis: chemokine and chemokine receptor modulation by interferon-beta.

Authors:  Latt Latt Aung; Patricia Fitzgerald-Bocarsly; Suhayl Dhib-Jalbut; Konstantin Balashov
Journal:  J Neuroimmunol       Date:  2010-09-14       Impact factor: 3.478

Review 3.  The Lymphotoxin Network: orchestrating a type I interferon response to optimize adaptive immunity.

Authors:  Jennifer L Gommerman; Jeffrey L Browning; Carl F Ware
Journal:  Cytokine Growth Factor Rev       Date:  2014-03-12       Impact factor: 7.638

Review 4.  The role of dendritic cells in CNS autoimmunity.

Authors:  Alla L Zozulya; Benjamin D Clarkson; Sonja Ortler; Zsuzsanna Fabry; Heinz Wiendl
Journal:  J Mol Med (Berl)       Date:  2010-03-09       Impact factor: 4.599

Review 5.  Plasmacytoid dendritic cells and immunotherapy in multiple sclerosis.

Authors:  Felipe von Glehn; Leonilda M Santos; Konstantin E Balashov
Journal:  Immunotherapy       Date:  2012-10       Impact factor: 4.196

6.  Disialogangliosides and TNFα alter gene expression for cytokines and chemokines in primary brain cell cultures.

Authors:  Donna M Byers; John C Gorbet; Louis N Irwin
Journal:  Neurochem Res       Date:  2011-10-01       Impact factor: 3.996

7.  Interferon-β inhibits toll-like receptor 9 processing in multiple sclerosis.

Authors:  Konstantin E Balashov; Latt Latt Aung; Adi Vaknin-Dembinsky; Suhayl Dhib-Jalbut; Howard L Weiner
Journal:  Ann Neurol       Date:  2010-12       Impact factor: 10.422

Review 8.  Dendritic cells as therapeutic targets in neuroinflammation.

Authors:  Felix Luessi; Frauke Zipp; Esther Witsch
Journal:  Cell Mol Life Sci       Date:  2016-03-12       Impact factor: 9.261

Review 9.  The role of dendritic cells in multiple sclerosis.

Authors:  Gregory F Wu; Terri M Laufer
Journal:  Curr Neurol Neurosci Rep       Date:  2007-05       Impact factor: 5.081

Review 10.  Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders.

Authors:  Yahya E Choonara; Viness Pillay; Lisa C Du Toit; Girish Modi; Dinesh Naidoo; Valence M K Ndesendo; Sibongile R Sibambo
Journal:  Int J Mol Sci       Date:  2009-06-03       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.